MXC
Director Trades
| Date | Director | Value |
|---|
Company News
MGC Pharmaceuticals receives cannabis research and import permit grants in Australia
MGC Pharmaceuticals (ASX: MXC) has reached yet another regulatory milestone after the biopharmaceutical company confirmed it has been granted a cannabis research cultivation permit by the Australian Office of Drug Control (ODC). The grant follows MGC’s cannabis research licence granted last year, in addition to a separate import licence obtained last week and is set to […]
MGC Pharma expands ArtemiC Phase II trial to include COVID-19 patients in India
MGC Pharmaceuticals (ASX: MXC) has confirmed the footprint of a Phase II trial into the efficacy of its ArtemiC anti-inflammatory medicated spray on the COVID-19 virus will be expanded to include the Mahatma Gandhi Mission Medical College and Hospital in India. The company will commence recruiting patients from the hospital in Aurangabad this month for […]
MGC Pharma and Micelle Technology to begin clinical trial using anti-infective drug on COVID-19 patients
MGC Pharmaceuticals (ASX: MXC) is about to kick-off a phase II clinical trial evaluating a natural anti-infective drug on COVID-19 patients. Israel’s Nazareth Hospital Human Research Ethics Committee has given the go-ahead for MGC to proceed with a trial to evaluate the safety and efficacy of the natural ArtemiC drug, which is designed to target […]
MGC Pharmaceuticals presents ‘ground-breaking’ research into effect of cannabis on brain cancer
Biopharmaceutical company MGC Pharmaceuticals (ASX: MXC) has completed what it calls “ground-breaking research” that highlights the effectiveness of cannabinoids on various brain cancers. Earlier today, the “seed to pharmacy” bio-pharma company published what it calls “new facts” on the pre-clinical research which highlighted the positive impact of using specific cannabinoid formulations in the treatment of glioblastoma – […]
MGC Pharma officially enters UK with CannEpil distribution to begin immediately
Medicinal cannabis producer MGC Pharmaceuticals’ (ASX: MXC) first CannEpil shipment to the UK has landed on British soil and will be immediately distributed to the country’s pharmacies and patients. MGC Pharma’s cannabinoid-based CannEpil product is an oil solution that can be taken orally to relieve the symptoms of severe epilepsy – particularly where conventional medications […]
MGC Pharmaceuticals enters Chinese market with CBD products
Biopharmaceutical company MGC Pharmaceuticals (ASX: MXC) is entering the Chinese health market, inking a deal with e-commerce import platform YuShop Global to sell its range of cannabis-based nutraceutical products. The company today announced the signing of a marketing and distribution agreement, under which YuShop will provide a “turn-key” service including sales, marketing, logistics and customer […]
MGC Pharmaceuticals receives TGA approval to market its CannEpil medicinal cannabis product in Australia
Aspiring bio-pharmaceutical company MGC Pharmaceuticals (ASX: MXC) has received formal authorisation to supply its CannEpil product through specialist prescribers under the ‘Authorised Prescriber Scheme’ as regulated by the Therapeutic Goods Administration (TGA). The TGA authorisation follows Human Research Ethics Committee endorsement from St Vincent’s Hospital Melbourne earlier this year for CannEpil to be used in […]
MGC Pharmaceuticals positions cannabis as a potential treatment in the fight against dementia
Biopharma developer MGC Pharmaceuticals (ASX: MXC) plans to apply the potential benefits of cannabis to mitigate the impact of dementia. Earlier this morning, the company announced it has been granted “full ethics approval” to conduct a phase 2 clinical trial into the effects of CogniCann, MGC’s certified, pharmaceutical-grade medicinal cannabis product developed for patients with […]
UK’s Harvey Nichols to expand MGC Pharmaceuticals CBD Derma range
MGC Pharmaceuticals (ASX: MXC) has received strong commercial news this morning with the news that UK-based retailer Harvey Nichols has decided to expand the sale of MGC’s premium cannabidiol (CBD) ‘Derma and Derma Plus’ collections to two further stores within the UK. Harvey Nichols has confirmed that it intends to stock MGC’s products at two […]
MGC Pharmaceuticals receives key medical cannabis certification and manufacturing licence
Biopharma company MGC Pharmaceuticals (ASX: MXC) has received its GMP certification and formal manufacturing licence to produce Good Manufacturing Practice (GMP) grade medical cannabis medicines containing tetrahydrocannabinol (THC) and cannabidiol (CBD) APIs at its European production and compounding facility. In April, MGC took a big step towards securing its operational future by securing access to […]
Company Videos
No videos found.